TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10867377
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy
Study: 31487117
Drug: Topical Cadexomer
Normalized name: cadexomer iodine Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cadexomer Iodine for 2 weeks
Study: 31487117
Drug: Topical Cadexomer
Normalized name: cadexomer iodine Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cadexomer Iodine for 6 weeks
Study: 31487117
Drug: Topical Cadexomer
Normalized name: cadexomer iodine Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Cadexomer Iodine (both durations)
Study: 26123832
Drug: Multimodal maternal
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal maternal ADHD treatment (group psychotherapy plus open methylphenidate medication; treatment group (TG): n = 77)
Study: 19185670
Drug: 24/4 regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24/4 regimen of 20 mcg ethinyl estradiol and 1 mg norethindrone acetate
Study: 19185670
Drug: 21/7 regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 21/7 regimen of 20 mcg ethinyl estradiol and 1 mg norethindrone acetate
Study: 9159562
Drug: imidapril 10
Normalized name: imidapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: imidapril 10 mg day(‐1) + digoxin 0.25 mg day(‐1) (I + D)
Study: 9159562
Drug: imidapril 10
Normalized name: imidapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: imidapril 10 mg day(‐1) + placebo (I + P)
Study: 20306354
Drug: Narrative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrative therapy (8 sessions)
Study: 17947224
Drug: Sequential TAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential TAM
Study: 8836986
Drug: L-DOPA +
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-DOPA + L-threo-DOPS
Study: 8836986
Drug: L-threo-DOPS
Normalized name: L-DOPS
DrugBank: Droxidopa (DB06262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-threo-DOPS
Study: 6439648
Drug: Beta-carotene (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene (180 mg/week in 6 capsules)
Study: 6439648
Drug: Canthaxanthin (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canthaxanthin (180 mg/week in 6 capsules)
Study: 24707145
Drug: 10-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10-day regimen of amoxicillin 1 g, clarithromycin 500 mg, and rabeprazole 20 mg twice daily
Study: 2899496
Drug: Cefotaxime and
Normalized name: cefotaxime and beta-lactamase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime and metronidazole (75 mg/kg and 10 mg/kg intravenously in 3 doses at 12-hourly intervals) plus peritoneal lavage with cefotaxime 2 g/L during surgery (group 2)
Study: 25466655
Drug: Glutamine 30
Normalized name: glutamine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutamine 30 g/d (10 g powder, three times a day)
Study: 18060377
Drug: Compliance-enhancing program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compliance-enhancing program in patients with statin therapy
Study: 10738435
Drug: Antibiotic beads
Normalized name: Bead Tree Leaf
DrugBank: Azadirachta indica leaf (DB14352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic beads
Study: 10738435
Drug: Conventional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous antibiotics
Study: 10738435
Drug: Antibiotic beads
Normalized name: Bead Tree Leaf
DrugBank: Azadirachta indica leaf (DB14352)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic beads and intravenous antibiotics (nonrandomized third cohort)
Study: 2987294
Drug: Prednisone (glucocorticoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (glucocorticoid therapy)
Study: 30217229
Drug: Probiotic and
Normalized name: Florastor Advanced Probiotic And Digestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic and selenium co-supplementation (8×10^9 CFU/day probiotic plus 200 μg/day selenium)
Study: 14665500
Drug: Modafinil (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (200 to 400 mg qd)
Study: 11009043
Drug: Formoterol (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol (9 microg twice daily)
Study: 10451943
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (steroid, cyclophosphamide, and bennazipril)
Study: 10451943
Drug: LMWH (fraxiparin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMWH (fraxiparin) 60 anti Xa IU.kg‐1.day‐1 plus steroid, cyclophosphamide, and bennazipril
Study: 1589566
Drug: Zolpidem (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem (20 mg)
Study: 2667400
Drug: Triazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.5 mg)
Study: 29417761
Drug: M923 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: M923 (40 mg)
Study: 27468258
Drug: BCAAs and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAAs and CHO (3 g/d L-leucine, 1 g/d L-isoleucine, 2 g/d L-valine with 2 g of CHO; n=15)
Study: 27468258
Drug: CHO only
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO only (42 g of CHO; n=15)
Study: 20645530
Drug: Ustekinumab 22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 22.5 or 45 mg/kg s.c. (n = 32)
Study: 20645530
Drug: Ustekinumab 0.09-4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 0.09-4.5 mg/kg i.v. or 0.27-2.7 mg/kg s.c. (n = 46)
Study: 16288390
Drug: Moxifloxacin (MXF)
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moxifloxacin (MXF) 400 mg once daily intravenously, possibly followed by oral tablets
Study: 16288390
Drug: Ceftriaxone (CTRX)
DrugBank: Ceftriaxone (DB01212)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftriaxone (CTRX) 2 g intravenously once daily with or without Erythromycin (ERY) 1 g intravenously every 6-8 h
Study: 2929629
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg caffeine
Study: 26096318
Drug: Task-Based Mirror
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-Based Mirror Therapy (TBMT)
Study: 19737441
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg mecamylamine
Study: 17691588
Drug: Iron(III)-hydroxide polymaltose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron(III)-hydroxide polymaltose complex (IPC, Maltofer) with tetracycline (2 x 250 mg capsules)
Study: 17691588
Drug: Tetracycline alone
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetracycline alone (2 x 250 mg capsules)
Study: 12576956
Drug: Intravenous nicorandil
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous nicorandil (6 mg/hr continuous infusion for 60 mins)
Study: 12576956
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal saline, 6 mL/hr continuous infusion)
Study: 31013851
Drug: Low-dose CW
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CW (300 mg/d)
Study: 31013851
Drug: High-dose CW
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CW (600 mg/d)
Study: 20825373
Drug: Weekly severity
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly severity ratings of manic symptoms
Study: 19325997
Drug: 0.25 microg
Normalized name: calcitriol 0.25 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 microg oral alphacalcidol twice daily for 6 months
Study: 20181806
Drug: Fish oils
Normalized name: fish oils
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oils (4 g/d)
Study: 18566295
Drug: Atorvastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (40 mg/d)
Study: 16825679
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Fish oils and Atorvastatin
Study: 10614892
Drug: Computer-assisted management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted management of warfarin therapy
Study: 15449753
Drug: Morphine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (1 mg/kg)
Study: 30301252
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SRS and ICIs
Study: 26997655
Drug: Low-dose VPA
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose VPA (800 mg/day)
Study: 26997655
Drug: High-dose VPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose VPA (1200 mg/day)
Study: 24586256
Drug: TRC150094 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRC150094 (50 mg once daily)
Study: 20061421
Drug: GH +
Normalized name: Delsym Cough + Cold Daytime
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH + Ox 0.03 mg/kg . d
Study: 11692346
Drug: Placebo (water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (water spray)
Study: 2239934
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (r‐HuEPO) therapy for 18 +/- 6 weeks
Study: 27867128
Drug: Meropenem 2
Normalized name: meropenem 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem 2 g every 8 hours
Study: 16555941
Drug: 375 ml
Normalized name: isopropyl alcohol 0.0375 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 ml of white wine daily
Study: 9692103
Drug: Amoxycillin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (500 mg t.d.s.)
Study: 3167404
Drug: Clomipramine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine treatment with self-exposure instructions
Study: 20388201
Drug: Taxane-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane-based chemotherapy (Carboplatin AUC5 and Docetaxel 75 mg/m2 administered intravenously in a 3-weekly schedule)
Study: 16840728
Drug: Intensive induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive induction and consolidation treatment according to a single protocol for patients above age 60
Study: 14564333
Drug: Heparin-coated stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated stent
Study: 1631174
Drug: Potassium depletion
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium depletion treatment (KD0, KD1, KD2)
Study: 1631174
Drug: Potassium depletion
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium depletion treatment (KD2)
Study: 6386253
Drug: Dihydroquinidine (DQ)
Normalized name: Hydroquinidine
DrugBank: Hydroquinidine (DB15300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydroquinidine (DQ) 300 mg t.i.d.
Study: 6386253
Drug: Disopyramide (D)
DrugBank: Disopyramide (DB00280)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Disopyramide (D) 200 mg t.i.d.
Study: 30672383
Drug: rs3842761 GG/CC+CG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rs3842761 GG/CC+CG in FIGO stage III‐IV
Study: 25266206
Drug: High-protein yogurt
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein yogurt (14 g protein/25 g CHO/0 g fat)
Study: 15337553
Drug: Oral aloe
Normalized name: Aloe
DrugBank: Aloe ferox leaf (DB14257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aloe vera gel
Study: 2642754
Drug: Probucol (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probucol (500 mg b.i.d.)
Study: 2642754
Drug: Lovastatin plus
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin plus colestipol (10 g b.i.d.)
Study: 2642754
Drug: Lovastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (80 mg/day) plus colestipol (10 g b.i.d.)
Study: 10394450
Drug: Water administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water administration
Study: 17697100
Drug: Cholinesterase inhibitor
Normalized name: Acetylcholinesterase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitor therapy (ChEI)
Study: 14995919
Drug: Acupuncture (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (n = 37), stimulated once or twice a week until delivery or complete recovery
Study: 11994555
Drug: GPIIb/IIIa antagonist,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPIIb/IIIa antagonist, orbofiban
Study: 2334579
Drug: Tranquilizer (clobazam)
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranquilizer (clobazam)
Study: 30137547
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations (MR and IR)
Study: 18815438
Drug: Mixed amphetamine
Normalized name: mixed amphetamine salts 5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed amphetamine salts-extended release (MAS XR) 50 mg/day
Study: 22519922
Drug: Atomoxetine 80
Normalized name: atomoxetine 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 80 mg/day
Study: 16021360
Drug: 250 mcg
Normalized name: Nplate 250 MCG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mcg IFNbeta‐1b every other day
Study: 2618318
Drug: Halothane inhalation
Normalized name: Halothane Inhalation Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halothane inhalation anaesthesia in combination with nitrous oxide and oxygen
Study: 383272
Drug: 100 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/m2 q 3 wk
Study: 383272
Drug: 200 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/m2 q 6 wk
Study: 25671254
Drug: Lenvatinib (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib (24 mg per day in 28-day cycles)
Study: 22559867
Drug: 0.005% latanoprost
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.005% latanoprost once daily
Study: 8743003
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol twice daily
Study: 1996894
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg daily for six days
Study: 1996894
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg every 12 hours for three doses
Study: 17086021
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg/d
Study: 6648735
Drug: Hydrochlorothiazide 25
Normalized name: hydrochlorothiazide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 25 mg plus triamterene 50 mg
Study: 6648735
Drug: Amiloride hydrochloride
Normalized name: Amiloride Hydrochloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amiloride hydrochloride 5 mg plus hydrochlorothiazide 50 mg
Study: 6648735
Drug: Chlorthalidone 50
Normalized name: chlorthalidone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 50 mg/d
Study: 6873133
Drug: Indapamide 2.5
Normalized name: indapamide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 2.5 mg/d
Study: 30792142
Drug: Iron-rich meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-rich meal (43 mg of iron)
Study: 25544294
Drug: Lidocaine plus
Normalized name: Icy Hot Lidocaine Plus Menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine plus dexmedetomidine solution
Study: 25544294
Drug: Lidocaine solution
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine solution
Study: 21443422
Drug: Acetyl-L-carnitine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (2 g twice a day for 90 days)
Study: 8527290
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg
Study: 15319645
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (triple treatment and placebo)
Study: 17714334
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BTX) treatment
Study: 9173954
Drug: CHO supplement
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO supplement (1 g/kg) immediately postexercise
Study: 9173954
Drug: CHO supplement
Normalized name: G-CSF (CHO cell derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHO supplement (1 g/kg) 1 h postexercise
Study: 3099002
Drug: Complex and
Normalized name: vitamin B complex and C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex and elemental enteral formulas at infusion rates of 50 to 150 kcal/hr
Study: 28728683
Drug: Conventional HF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional HF treatment combined with an individualized nutritional intervention
Study: 28728683
Drug: Conventional HF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional HF treatment
Study: 22094904
Drug: BMMSC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMMSC treatment and CD treatment
Study: 12692844
Drug: p53 immunostaining
Approvals — FDA: no, EMA: no, PMDA: no
Description: p53 immunostaining (using mouse monoclonal antibody pAb1801)
Study: 1516415
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg tablets, three times daily for 48 hours prior to testing)
Study: 3523041
Drug: Postoperatively administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperatively administered plasma proteins
Study: 22237175
Drug: Cytomegalovirus therapeutic
Normalized name: cytomegalovirus immunoglobulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytomegalovirus therapeutic DNA vaccine (TransVax) administered before conditioning and at 1, 3, and 6 months after transplantation.
Study: 19292590
Drug: lopinavir/ritonavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir monotherapy
Study: 8830827
Drug: rhuIL‐1R therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhuIL‐1R therapy
Study: 3910302
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 40 mg/d
Study: 3910302
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 80 mg/d
Study: 3910302
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 120 mg/d
Study: 23945510
Drug: Intranasal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine 1 μg/kg
Study: 23812579
Drug: Prolapse surgery
Normalized name: Prolate
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prolapse surgery with concurrent tension-free vaginal tape (TVT)
Study: 20138267
Drug: AMH level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMH level ≥3.01 ng/mL
Study: 20138267
Drug: AMH level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMH level ≥3.2 ng/mL
Study: 11888456
Drug: Hypoventilation (tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoventilation (tidal volume 4 mL/kg, respiratory rate 15/min)
Study: 11888456
Drug: Normoventilation (tidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normoventilation (tidal volume 10 mL/kg, respiratory rate 10/min)
Study: 9861280
Drug: Mectizan (ivermectin)
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mectizan (ivermectin) treatment every 3 months
Study: 9861280
Drug: Mectizan (ivermectin)
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mectizan (ivermectin) treatment every 6 months
Study: 9861280
Drug: Mectizan (ivermectin)
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mectizan (ivermectin) treatment every 12 months
Study: 9861280
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment every 3 months
Study: 342174
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose fenoterol (5.6 microgram)
Study: 342174
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose fenoterol (32.7 microgram)
Study: 342174
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose fenoterol (127.5 microgram)
Study: 28133906
Drug: Tacrolimus-based therapy
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus-based therapy
Study: 23682170
Drug: Walking training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walking training including balance exercises and lower limb strength activities twice a week for 4 months
Study: 20704266
Drug: Bead formulation
Normalized name: Beads
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bead formulation with faster dissolution rate (80% dissolved in 41 min)
Study: 20704266
Drug: Bead formulation
Normalized name: Beads
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bead formulation with slower dissolution rate (80% dissolved in 114 min)
Study: 10665727
Drug: Miller‐Galante II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miller‐Galante II (MG II)
Study: 29665620
Drug: Anti-inflammatory nutrition
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory nutrition supplement (AINS) consisting of long chain n-3 PUFA, vitamin C, α-tocopherol, green tea extract, and lycopene for 8 weeks
Study: 12225705
Drug: Placebo nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nicotine nasal spray
Study: 15914133
Drug: Suppository
Normalized name: Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suppository
Study: 20739719
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (NaHCO₃) 0.3 g/kg body weight
Study: 10506264
Drug: Acetaminophen (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (12 mg/kg)
Study: 29140929
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (nocebo pain)